Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Control Release. 2010 Sep 1;146(2):164-74. doi: 10.1016/j.jconrel.2010.04.008. Epub 2010 Apr 10.

Translational considerations for cancer nanomedicine.

Author information

  • 1Nanotechnology Characterization Laboratory, Advanced Technology Program, SAIC-Frederick Inc., NCI-Frederick, PO Box B, Frederick, MD 21702, USA. sternstephan@mail.nih.gov

Abstract

There are many important considerations during preclinical development of cancer nanomedicines, including: 1) unique aspects of animal study design; 2) the difficulties in evaluating biological potency, especially for complex formulations; 3) the importance of analytical methods that can determine platform stability in vivo, and differentiate bound and free active pharmaceutical ingredient (API) in biological matrices; and 4) the appropriateness of current dose scaling techniques for estimation of clinical first-in-man dose from preclinical data. Biologics share many commonalities with nanotechnology products with regard to complexity and biological attributes, and can, in some cases, provide context for dealing with these preclinical issues. In other instances, such as the case of in vivo stability analysis, new approaches are required. This paper will discuss the significance of these preclinical issues, and present examples of current methods and best practices for addressing them. Where possible, these recommendations are justified using the existing regulatory guidance literature.

Copyright 2010 Elsevier B.V. All rights reserved.

PMID:
20385183
[PubMed - indexed for MEDLINE]
PMCID:
PMC2921639
Free PMC Article

Images from this publication.See all images (10)Free text

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk